FDA Drug Recalls

Recalls / Class II

Class IID-0277-2025

Product

Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC 57237-018-99

Brand name
Duloxetine
Generic name
Duloxetine Hydrochloride
Active ingredient
Duloxetine Hydrochloride
Route
Oral
NDCs
57237-017, 57237-018, 57237-019
FDA application
ANDA090778
Affected lot / code info
Lot #: DTB23111A, Exp 8/31/2025

Why it was recalled

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Recalling firm

Firm
Rising Pharma Holding, Inc.
Manufacturer
Rising Pharma Holdings, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
2 Tower Center Blvd Ste 1401, N/A, East Brunswick, New Jersey 08816-1149

Distribution

Quantity
1223 bottles
Distribution pattern
Nationwide in the USA.

Timeline

Recall initiated
2025-03-05
FDA classified
2025-03-14
Posted by FDA
2025-03-26
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0277-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Duloxetine · FDA Drug Recalls